TABLE 167Mixed-treatment comparison – MMSE at 24–26 weeks (mean change from baseline; LOCF data only): results

TechnologyVs placeboProbability most effective
Effect95% CIProbability more effective than placebo
Placebo0.001
Donepezil1.4600.581 to 2.4200.9950.741
Galantamine
Rivastigmine1.1370.152 to 2.1600.9820.258
Memantine

From: Appendix 9, Mixed-treatment comparisons performed in specified measurement populations

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.